Teleflex Q3 2026 Earnings Conference Call - TELEFLEX INC

Explicit Guidance:

• 2026 Revenue Growth: Maintained at 3.5%–4.5% pro forma adjusted constant currency (unchanged from prior guidance; excludes impact of pending divestiture proceeds).
• 2026 Adjusted EPS: Increased to $7.50–$7.75 (prior range: $6.90–$7.20); includes a $0.31 benefit from IEPA tariff refunds and current share count reductions.
• 2026 Adjusted Operating Margin: Expected at ~20%, inclusive of the $16.5M tariff refund benefit.
• 2027 Operating Margin Outlook: Anticipated to reach ~23% in the first year following the close of the acute care and interventional urology divestiture, driven by transition service agreements (TSAs) offsetting stranded costs.
• 2026 Net Interest Expense: Expected at approximately $85 million for the full year.
• 2026 Adjusted Tax Rate: Expected at ~11.5% (down from prior 12.25% estimate).
• 2026 Share Count: Expected at ~42.5 million shares; includes repurchases to date but excludes additional buybacks for the remainder of the year.
• 2026 Free Cash Flow/Capex Implications: $800 million debt reduction committed; $1 billion share repurchase authorization remains, with $400 million remaining available as of November 5, 2026.
• Restructuring Savings: Multi-year plan targeting $50 million in annual pre-tax cost savings by mid-2028, currently on track.

Business-Segment Outlook:

• Interventional: Expected to see sequential constant currency growth improvement in Q4 2026 and into 2027. Goal is to return to market growth rates (mid-single digits) by 2027, driven by completion of integration, leadership under Jason Fontana, and new product introductions (FreeZolve).
• Vascular: Continued solid growth expected, though Q4 may see moderated growth due to inventory normalization following the lidocaine recall.
• Surgical: Solid growth expected; growth may moderate compared to H1 due to high-comparison new instrument portfolio acceleration in mid-2025.
• Product Launches:
  • FreeZolve: Enrollment complete in Biomag-2 (data readout expected late 2027); U.S. pivotal trial (Biomac-3) underway. FDA Breakthrough Device Designation received.
  • EasyPlaz: Revenue expected to be immaterial in 2026, with contribution beginning in 2027. Targeting modest revenue ramp over subsequent years after market building.
• Divestitures:
  • OEM: Closing expected to drive immediate margin expansion and debt reduction.
  • Acute Care & Interventional Urology: Confident in closing; timing may extend into 2027 due to regulatory review (FTC second request). TSAs and MSAs will remain effective post-close.

Market and Competitive Outlook:

• EasyPlaz Market Size: Updated long-term U.S. TAM to at least $200 million (up from previous ~$100 million estimates).
• Competitive Positioning: EasyPlaz holds first-mover advantage as the only FDA-licensed freeze-dried plasma; expected to set the standard against future competitors using glass containers.
• Interventional Market Growth: Anticipated to grow at mid-single digits; Teleflex aims to outperform by targeting higher-growth subsegments and expanding geographic presence in under-penetrated regions.
• Tariffs: Expected to incur ~$30 million in tariffs in 2027, consistent with current year levels; no special agreements anticipated similar to BD's 232 relief.

Macro / Industry Outlook:

• FX Impact: 2026 foreign exchange impact on reported revenue expected to be a $9 million–$10 million benefit (down from prior $14 million estimate).
• Regulatory/Tariffs: Management advises against speculation on future 232 investigations; guidance remains based on current tariff structures.
• Interest Rates/Capital Markets: Lower interest expense expected in 2027 due to debt reduction ($700M term loan paid off, revolver drawdown reduced).
• Government/Military Contracts: EasyPlaz first priority is securing contracts with the U.S. Department of War and military; negotiations ongoing.

Strategic Initiatives:

• Organizational Restructuring: Implementation of a global business unit structure (Vascular, Interventional, Surgical) to replace geographic matrix, aiming for sharper customer focus and faster decision-making.
• Leadership Changes: Jason Fontana appointed President of Interventional (effective Sept 14); Sean Salmon added to Board of Directors (effective Sept 8) with cardiovascular industry expertise.
• Capital Allocation: Continued focus on R&D investment increased from 5–6% to ~8% of revenue to fund substantive innovation (e.g., FreeZolve, EasyPlaz) and organic growth.
• M&A Strategy: No substantive M&A anticipated in the near term due to focus on foundational transformation (interventional integration, divestiture closure); will revisit opportunistic tuck-in acquisitions once operational stability is achieved.
• R&D Ramp: Significant startup costs anticipated in Q4 2026 for Biomag-3 studies, temporarily impacting margins.

Risks and Headwinds to Outlook:

• Divestiture Timing: Failure or delay in closing the acute care/urology divestiture could delay capital deployment, debt reduction, and the anticipated 23% margin step-up in 2027.
• Integration Disruption: Interventional business faces ongoing headwinds from order-to-cash transition (10% of customers remaining), distributor transitions (13% remaining), and sales force ramp-up (6-month productivity lag for new hires).
• Supply Chain/Capacity: EasyPlaz scaling requires a multi-year capacity build; potential supply constraints in short-to-mid term as priority is assigned to U.S. government/military orders.
• Product Commercialization: EasyPlaz revenue ramp is expected to be slow; pricing not yet finalized, impacting early margin profiles.
• Regulatory Uncertainty: FTC review timeline for the urology divestiture remains subject to external process beyond management control.

Management Tone on the Future:

• Confidence Level: High confidence in long-term margin expansion (23% in 2027) and earnings growth, citing "tangible milestones" and "energized" employees.
• Hedges/Prudence: Explicitly avoids giving 2027 specific numbers, citing the need to close the urology deal and finalize planning first. Avoids ranking integration headwinds by revenue impact.
• Sentiment: Optimistic about the "new focused Teleflex," emphasizing a shift from transition to sustainable growth, innovation, and capital efficiency.

Miscellaneous:

• Share Buybacks: $350 million repurchased in Q3 (including $100M additional to prior plan); $250M accelerated program completed, $100M open market repurchases executed.
• Tariff Refund: One-time $16.5M benefit to Q3 2026 cost of sales; $9M–$10M total annual benefit expected in 2026.
• Stranded Costs: Expectation to further mitigate stranded costs from strategic divestitures post-close, further supporting margin expansion.